Exploration of Targeted Anti-tumor Therapy · 2024 · 26 citations · 85 references
MedicineCancer BiologyImmunologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer ImmunotherapyImmunosuppressionImmunosuppressive AgentsImmunosuppressive TherapyMyeloid-derived Suppressor CellsImmunosuppressive FunctionImmunosuppressive Myeloid CellsMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell ImmunosuppressionMyeloid-derived Suppressor Cell Therapy ResistanceMyeloid-derived Suppressor Cell-mediated SuppressionNitric OxideTherapeutic Resistance Mechanisms
Cancer is the leading cause of death globally superseded only by cardiovascular diseases, and novel strategies to overcome therapeutic resistance against existing cancer treatments are urgently required. Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells with potent immunosuppressive capacity against well-established anti-tumour effectors such as natural killer cells (NK cells) and T cells thereby promoting cancer initiation and progression. Critically, MDSCs are readily identified in almost all tumour types and human cancer patients, and numerous studies in the past decade have recognised their role in contributing to therapeutic resistance against all four pillars of modern cancer treatment, namely surgery, chemotherapy, radiotherapy and immunotherapy. MDSCs suppress anti-tumour immunity through a plethora of mechanisms including the well-characterised arginase 1 (Arg1), inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS)-mediated pathways, along with several other more recently discovered. MDSCs are largely absent in healthy homeostatic states and predominantly exist in pathological conditions, making them attractive therapeutic targets. However, the lack of specific markers identified for MDSCs to date greatly hindered therapeutic development, and currently there are no clinically approved drugs that specifically target MDSCs. Methods to deplete MDSCs clinically and inhibit their immunosuppressive function will be crucial in advancing cancer treatment and to overcome treatment resistance. This review provides a detailed overview of the current understandings behind the mechanisms of MDSC-mediated suppression of anti-tumour immunity, and discusses potential strategies to target MDSC immunosuppressive mechanisms to overcome therapeutic resistance.
85
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Franck Pagès, Anne Berger, Matthieu Camus et al. · New England Journal of Medicine · 2005 · 2.1K citations · Full text
Medicine, Immunology, Oncology +17
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Roger Geiger, Jan C. Rieckmann, Tobias Wolf et al. · Cell · 2016 · 1.7K citations · Full text
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
Yoshitaka Naito, Kazuya Saito, Kenichi Shiiba et al. · PubMed · 1998 · 1.2K citations